9
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TQ0078 |
CDK-IN-2
CDK inhibitor II |
CDK | Cell Cycle/Checkpoint |
CDK-IN-2 (CDK inhibitor II) 是一种有效且特异性的 CDK9 抑制剂,IC50小于8 nM。 | |||
T36933 |
Cdk2 Inhibitor II
Cdk2 Inhibitor II,CDK2-IN-3 |
CDK | Cell Cycle/Checkpoint |
Cdk2 Inhibitor II 是一种具有选择性和有效性的 CDK2 抑制剂,50 为 60 nM。 | |||
T22461 |
YKL-5-124
|
CDK | Cell Cycle/Checkpoint |
YKL-5-124 是选择性不可逆CDK7共价抑制剂,对CDK7和CDK7/Mat1/CycH 的IC50分别为 53.5 nM 和 9.7 nM。它诱导强烈的细胞周期停滞,并抑制 E2F 驱动的基因表达。它对 CDK7 的生化和细胞选择性优于 CDK12/13。它对CDK7的选择性比 CDK9 和 CDK2 高 100 倍以上。 | |||
T8972 |
FIT-039
|
Others; DNA/RNA Synthesis; CDK; HSV | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Microbiology/Virology; Others |
FIT-039 是一种选择性和 ATP 竞争性的口服活性 CDK9 抑制剂,对CKD9/cyclin T1的IC50为 5.8 μM。它抑制HSV-1(IC50为 0.69 μM),HSV-2,人腺病毒和人CMV 的复制。它可抑制耐药性HSV 和其他 DNA 病毒,是有前途的抗病毒药物。 | |||
T3186 |
NU2058
O6-(Cyclohexylmethyl)guanine,O(6)-Cyclohexylmethylguanine |
Topoisomerase; CDK | Cell Cycle/Checkpoint; DNA Damage/DNA Repair |
NU2058 (O(6)-Cyclohexylmethylguanine) 是一种基于鸟嘌呤的 CDK 抑制剂,抑制 CDK2 和 CDK1 的IC50值分别为 17 μM 和 26 μM。它也抑制 DNA 拓扑异构酶 II ATPase 活性,具有抗癌活性。 | |||
T6187 |
TDZD-8
GSK-3β Inhibitor I,NP 01139 |
GSK-3 | PI3K/Akt/mTOR signaling; Stem Cells |
TDZD-8 (NP 01139) 是抑制GSK-3β的抑制剂,其 IC50=2 μM。它对 Cdk-1/cyclin B,CK-II,PKA 和 PKC 的作用较弱,IC50值均 >100 μM。 | |||
T62235 | CDK-IN-9 | ||
CDK-IN-9 (compound 24) 是一种 CDK 的有效抑制剂。CDK-IN-9 也是一种能够诱导 CDK12 和 DDB1 相互作用的分子胶, 能够作用于 CDK2/E (IC50: 4 nM) 。CDK-IN-9 能够导致细胞周期蛋白 K (cyclin K) 的多泛素化及其随后的降解。CDK-IN-9 可以利用去磷酸化视网膜母细胞瘤蛋白和RNA 聚合酶 II,进而诱导细胞凋亡 (apoptosis)。 | |||
T70988 |
Ibulocydine
|
||
Ibulocydine is a potent CDK inhibitor. Ibulocydine has high activity against Cdk7/cyclin H/Mat1 and Cdk9/cyclin T. Ibulocydine inhibited the growth of HCC cells more effectively than other Cdk inhibitors, including olomoucine and roscovitine, whereas ibulocydine as well as the other Cdk inhibitors and BMK-Y101 minimally influenced the growth of normal hepatocyte cells. Ibulocydine induced apoptosis in HCC cells, most likely by inhibiting Cdk7 and Cdk9. In vitro treatment of HCC cells with ibuloc... | |||
T71549 |
RKS-262
|
||
RKS262 is a specific cyclin/CDK inhibitor. RKS262 was identified by structural optimization of Nifurtimox which is currently undergoing phase II clinical trials to treat high-risk neuroblastoma. In a NCI(60) cell-line assay RKS262 exhibited significant cytotoxicity in ovarian cancer cells and a variety of other cell lines exceeding effects of commercial drugs such as cisplatin, 5-FU, cyclophosphamide or sapacitabine. Various leukemia cell-lines were most sensitive (GI(50): ~ 10 nM) while several... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T17143 |
Toyocamycin
丰加霉素,Vengicide |
Apoptosis; Others; IRE1; Antibiotic; Antifungal | Apoptosis; Cell Cycle/Checkpoint; Microbiology/Virology; Others |
Toyocamycin (Vengicide) 是放线菌类产生的腺苷类似物,为 X 盒结合蛋白 1 (XBP1) 抑制剂,抑制 IRE1α 诱导的 ATP 依赖性 XBP1 mRNA 的断裂,IC50值为 80 nM。它还诱导凋亡。 |